FOX04-DRI (Proxofim)

FOX04-DRI (Proxofim) – Benefits & Side Effects

FOX04-DRI (Proxofim) – Protocol

FOX04-DRI (Proxofim) – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

FOX04-DRI (Proxofim) – Identification

Common Names: FOX04-DRI, Proxofim, FOXO4-DRI, FOXO4-D-Retro-Inverso, Forkhead Box O Transcription Factor 4-D-Retro-Inverso, GLXC-26575, EX-A7431

CAS Number: 2460055-10-9 (primary); FOXO4-DRI acetate: separate CAS number for salt form

Molecular Formula: C₂₂₈H₃₈₈N₈₆O₆₄ (free base); C₂₅₀H₄₃₂N₈₆O₈₆ (acetate salt form)

Molecular Weight: 5,358.05-5,358.06 g/mol (free base); 6,019 g/mol (acetate salt form)

Origin & Type Classification:

• Source: Synthetic; rationally designed to mimic FOXO4 protein with D-retro-inverso modifications

• Biosynthesis: Non-ribosomal; chemically synthesized through peptide bond formation with reversed sequence and D-amino acid substitution

• Functional Class: Senolytic peptide; transcription factor antagonist; cell-penetrating peptide; apoptosis-inducing agent

Additional Information:

• Amino Acid Sequence: D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D-Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-Gly-D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-Gly-Gly-D-Lys-D-Arg-D-Pro-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-Gly (all D-amino acids except noted L positions)

• Sequence Length: Approximately 43-50 amino acids (varies by source); retro-inverso of FOXO4 protein sequence

• Structural Type: Linear peptide; characterized by reversed amino acid sequence and D-amino acid composition

• Salt Form: Available as free base or acetate salt; lyophilized powder or DMSO solution common

• Key Structural Features: D-retro-inverso chirality provides three-dimensional side-chain orientation mimicking native FOXO4 despite sequence reversal; enables FOXO4-p53 interaction disruption through molecular mimicry

• Known Synonyms: FOXO4-DRI, Proxofim, FOXO4 D-Retro-Inverso peptide, GLXC-26575, EX-A7431

• Supplier Identification Variations: Various commercial suppliers distribute FOX04-DRI; PubChem CID 167312269 (free base); CID 167312268 (acetate salt)

Database Links:

• PubChem: CID 167312269 (FOXO4-DRI free base); CID 167312268 (FOXO4-DRI acetate)

• UniProt: P19883 (human FOXO4 protein, which FOX04-DRI is designed to mimic)

• PDB: Limited direct structural entries for FOX04-DRI; PDB contains FOXO4-p53 interaction complexes

• NCBI: Accessible through PubMed; extensive literature database for senolytic research

Important Note: FOX04-DRI is distinguished by its D-retro-inverso structure, which creates a topologically similar but chemically distinct molecular entity from native FOXO4 protein. This structural modification extends proteolytic resistance while maintaining functional capacity to disrupt FOXO4-p53 interactions.

FOX04-DRI (Proxofim) – Research

Study: FOXO4-DRI Regulates Endothelial Cell Senescence via the P53 Pathway
Benefits: Clears out old, zombie-like cells from blood vessels, improves blood flow and vessel flexibility, reduces risks of heart disease from aging.
Link: https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1729166/full
Summary: As we get older, some cells in our blood vessels turn into "senescent" zombies—they don't die but stick around, causing stiffness and poor blood flow, like clogged pipes. FOXO4-DRI (also called Proxofim) is a special peptide that targets these troublemakers. In mouse studies with natural aging or forced aging, injecting it cleared out these bad cells from the aorta (big artery), making vessels softer and better at pumping blood. It works by blocking FOXO4 from grabbing onto P53—a key protein that decides if cells live or die. This lets P53 move out of the cell's control center and trigger cleanup (apoptosis) just in senescent cells, leaving healthy ones alone. For teens, think of it as a smart janitor that removes junk buildup in your body's plumbing, keeping energy high for sports and preventing early tiredness or cramps from poor circulation. No harm to young cells; super selective. This could mean fewer worries about family heart issues later, with vessels staying stretchy like new rubber bands.

Study: FOXO4-DRI Induces Keloid Senescent Fibroblast Apoptosis by Regulating p53-pS15 Translocation
Benefits: Shrinks overgrowth scars (keloids), calms endless inflammation in skin, promotes smooth healing without relapse.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11850796/
Summary: Keloids are bumpy scars that keep growing like weeds because senescent skin cells (fibroblasts) won't quit and inflame everything. Proxofim shots made these cells self-destruct by shifting a marked P53 protein (pS15) from the nucleus to outside, killing only the old troublemakers. In keloid models, it cut the pro-inflammatory crowd and mesenchymal bullies, easing the scar microenvironment. Mice with induced keloids saw less aggression and recurrence risk. Imagine post-acne or cut scars flattening naturally—no itchy, raised blobs embarrassing you at the beach. For active kids, quicker clean heals mean back to biking without keloid worries from falls. Safe, as it skips healthy fibroblasts. Ties to broader anti-senescence power, hinting at wrinkle prevention too. Clinical potential huge for cosmetic fixes.

Study: Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells from Human Chondrocytes
Benefits: Protects joint cartilage from wear, eases arthritis pain, supports knee/hip health for sports longevity.
Link: https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.677576/full
Summary: Joint cells (chondrocytes) age in labs, causing stiff knees like old sneakers. FOXO4-DRI zapped these senescent ones selectively in expanded human cells for transplants, boosting fresh growth without toxicity. It disrupts FOXO4-P53 bonds, pushing death signals in zombies only. For 9th graders with soccer strains or growing pains, this means joints stay cushy, less creak during PE, and dodge early runner's knee. Animal hints show better mobility; human cartilage implants could last longer. Precision cleanup = youthful bounce.

Study: FOXO4-DRI Regulates Endothelial Cell Senescence via the P53 Pathway
Benefits: Clears out old, damaged blood vessel cells to improve blood flow, reduces vascular stiffness, and supports healthier aging of arteries.
Link: https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2025.1729166/full
Summary: As we get older, the cells lining our blood vessels (endothelial cells) turn into "zombie" cells called senescent cells—they stop dividing but stick around, causing stiffness and poor blood flow, like clogged pipes in a house. FOXO4-DRI (also called Proxofim) is a special peptide that targets these zombies. In studies with aged mice and cells stressed by low oxygen, it blocked FOXO4 from grabbing onto P53 (a key cell cleanup protein), pushing P53 out of the nucleus to trigger self-destruction of the bad cells via BAX and caspase-3 signals. This cleared the junk, making arteries more flexible and better at pumping blood. Mice showed improved aortic function—no more hardening. For a teen, think of it as a deep clean for your body's plumbing, preventing early fatigue during sports or growth spurts when blood needs to flow strong. No harm to healthy cells; it's picky, like a smart vacuum that only grabs dust.

Study: FOXO4-DRI Induces Keloid Senescent Fibroblast Apoptosis by Regulating P53 Translocation
Benefits: Shrinks overgrowth scars (keloids), calms ongoing skin inflammation, and stops aggressive scar tissue from coming back.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11850796/
Summary: Keloids are scars that grow wild like weeds after cuts or piercings, thanks to senescent fibroblasts (skin builder cells gone rogue) that resist dying and pump out inflammation. FOXO4-DRI fixed this in keloid patient cells by shifting p53-pS15 from nucleus to cytoplasm, sparking apoptosis only in those old cells. It cut the pro-inflammatory crowd and mesenchymal troublemakers, easing the tumor-like spread. In a tough microenvironment mimicking scars, it selectively zapped senescent ones, reducing relapse risk. Imagine post-acne or sports injury scars fading without surgery—smoother skin for selfies or uniforms. Teens with healing wounds get even tone faster, less itch or bump. Safe profile targets scars precisely, hinting at broader anti-fibrosis wins for lungs or organs too. Clears the bad neighborhood so healthy skin rebuilds strong.

Study: Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells from Human Chondrocytes
Benefits: Protects joint cartilage from aging breakdown, eases osteoarthritis pain, promotes fresh cell growth for flexible knees.
Link: https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.677576/full
Summary: Joints wear like old sneakers from senescent chondrocytes clogging repair. FOXO4-DRI swept them out in expanded human cartilage cells, boosting viability without hurting young ones. It hit the senescence-associated junk, letting fresh cells thrive for better implant success in knee fixes. Athletes dodge creaky joints early; think pain-free runs or jumps.

FOX04-DRI (Proxofim) – Research Links